Precision NanoSystems (PNI) was acquired by Danaher Corporation's Life Sciences platform.
Details of the Acquisition
The acquisition of Precision NanoSystems (PNI) by Danaher Corporation's Life Sciences platform was finalized on June 1, 2021. This strategic move integrated PNI's advanced technologies into Danaher's broad portfolio of scientific and technological innovations.
About Precision NanoSystems (PNI)
Prior to its acquisition, Precision NanoSystems (PNI) was recognized as a global leader in providing technologies and solutions critical for the development of genetic medicines. Their expertise and products are particularly vital for the creation of:
- mRNA vaccines
- Therapeutics
PNI's contributions have been instrumental in advancing the field of genetic medicine, offering comprehensive tools that enable researchers and pharmaceutical companies to accelerate the development and delivery of novel treatments. Their work focuses on sophisticated nanoparticle delivery systems, which are essential for the safe and effective administration of genetic material into the body.
